Anastrover - a non-steroidal anti-estrogenic drug from the UK pharmaceutical company Vermodje.
The main active ingredient - anastrozole.
Product form - pills in a package of 25 pieces. 1 mg / tab.
The drug is a highly selective non-steroidal aromatase inhibitor third generation. In medical applications used in women from the UK in menopause: receiving Anastrover at a dose level of 1 ug estradiol decreases by 80% - 98%. At higher doses of the drug possesses androgenic and progestagenic activity, while no effect on the production of cortisol and aldosterone, requires receiving corticosteroids as replacement means. In comparison with aminoglugetimidom, Anastrover has a longer half-life, and when used in small doses warns feminization. The half-life of the active substance ranges from 40 to 50 hours. However, approximately 10% comes from the dosage used with urine within 72 hours (including metabolites and excreted). The main metabolite is Anastrover in the UK triazole, not having antiaromataznoy activity.